Latest APLMW ETF News Today | Earnings, Events & Price Alerts

APLMW News

Apollomics Confirms Ongoing Nasdaq Listing After Hearing Cancellation

Oct 15 2025Newsfilter

Nasdaq Suspends Trading of Apollomics Inc., Ltd.

Sep 17 2025Globenewswire

Apollomics Reports Full Year 2024 Financial Results and Highlights Clinical Updates and Business Progress

Apr 03 2025Newsfilter

Apollomics and LaunXP Announce Development and Commercialization Agreement for Vebreltinib

Mar 31 2025Newsfilter

Apollomics Announces Top-line Results for Phase 3 Bridging Trial of Uproleselan in China in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Dec 20 2024Newsfilter

Apollomics Regains Compliance with Nasdaq's Minimum Bid Price Requirement

Dec 10 2024Newsfilter

Apollomics' Announces Shareholder Approval and Effective Date for 1-for-100 Reverse Share Split

Nov 21 2024Newsfilter

Apollomics Reports First Half 2024 Financial Results and Highlights Vebreltinib Clinical Progress

Aug 14 2024Newsfilter

Apollomics Announces Positive Preliminary Data of Vebreltinib in Patients with Non-CNS MET Fusion Solid Tumors from its Phase 2 SPARTA Trial

Aug 13 2024Newsfilter

Apollomics Announces Positive Preliminary Data of Vebreltinib in Patients with Non-CNS MET Fusion Solid Tumors from its Phase 2 SPARTA Trial

Aug 13 2024Newsfilter

Apollomics to Present at the Canaccord Genuity 44th Annual Growth Conference

Aug 08 2024Newsfilter

Apollomics Granted 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Requirement

Jul 16 2024Newsfilter

Apollomics Announces Updated Strategic Focus and Leadership Team Changes

Jul 03 2024Newsfilter

Apollomics Announces Updated Strategic Focus and Leadership Team Changes

Jul 03 2024Newsfilter

Apollomics Announces Vebreltinib Data at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Jun 04 2024Newsfilter

Apollomics to Announce Full Year 2023 Financial Results and Host Conference Call on March 28, 2024

Mar 26 2024newsfilter

APLMW

APLMW

APLMW News

Apollomics Confirms Ongoing Nasdaq Listing After Hearing Cancellation

Nasdaq Suspends Trading of Apollomics Inc., Ltd.

Apollomics Reports Full Year 2024 Financial Results and Highlights Clinical Updates and Business Progress

Apollomics and LaunXP Announce Development and Commercialization Agreement for Vebreltinib

Apollomics Announces Top-line Results for Phase 3 Bridging Trial of Uproleselan in China in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Apollomics Regains Compliance with Nasdaq&#39;s Minimum Bid Price Requirement

Apollomics&#39; Announces Shareholder Approval and Effective Date for 1-for-100 Reverse Share Split

Apollomics Reports First Half 2024 Financial Results and Highlights Vebreltinib Clinical Progress

Apollomics Announces Positive Preliminary Data of Vebreltinib in Patients with Non-CNS MET Fusion Solid Tumors from its Phase 2 SPARTA Trial

Apollomics Announces Positive Preliminary Data of Vebreltinib in Patients with Non-CNS MET Fusion Solid Tumors from its Phase 2 SPARTA Trial

Apollomics to Present at the Canaccord Genuity 44th Annual Growth Conference

Apollomics Granted 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Requirement

Apollomics Announces Updated Strategic Focus and Leadership Team Changes

Apollomics Announces Updated Strategic Focus and Leadership Team Changes

Apollomics Announces Vebreltinib Data at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Apollomics to Announce Full Year 2023 Financial Results and Host Conference Call on March 28, 2024

Apollomics Regains Compliance with Nasdaq's Minimum Bid Price Requirement

Apollomics' Announces Shareholder Approval and Effective Date for 1-for-100 Reverse Share Split